Please Wait.....
Report
Global Influenza Market - Vaccines and Therapeutics
Market Report I 2025-04-08 I 387 Pages I Industry Experts
Influenza Market Trends and Outlook
Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses, mainly impacting the nose, throat, and lungs. The usual symptoms are fever, cough, sore throat, muscle aches, and fatigue, with severe cases potentially resulting in pneumonia or other infections, especially in high-risk groups like children, elderly individuals, and those suffering from chronic medical conditions. Influenza viruses are categorized into types A, B, C, and D, with Influenza A being the most concerning because of its ability to cause pandemics. The primary method of preventing the flu is through annual vaccination in the form of trivalent or quadrivalent vaccines aimed at the most common virus strains each season. Flu vaccines are produced using three primary technologies: egg-based, cell-based, and recombinant DNA methods. The egg-based method is still the most common, and recombinant DNA technology is increasingly popular because it is faster and more versatile.
Global Influenza market is estimated at US$9.6 billion in 2024 and expected to register a CAGR of 4.5% between 2024 and 2030 to reach US$12.4 billion in 2030. The influenza market is driven by global health initiatives, seasonal outbreaks of flu, and the need for preventive healthcare, leading to a steady demand for vaccines and antiviral treatments. Government immunization programs, increasing awareness, and ongoing R&D investments in vaccine innovation and pandemic preparedness are major market growth factors.
Advancements in vaccine technology, such as recombinant and cell-based formulations, have improved the effectiveness and availability of vaccine agents. Public-private partnerships, strategic collaborations, and global surveillance systems, including WHO and CDC initiatives, support the widespread vaccination efforts. An aging population and a rising number of chronic diseases further drive the need for vaccines. The market also benefits from enhanced distribution networks, regulatory incentives for quicker vaccine approvals, and emerging universal vaccine developments that target multiple strains of the virus. The COVID-19 pandemic heightened public awareness of vaccination, reinforcing demand for flu vaccines as a preventive measure. Investments in antiviral drug development, such as next-generation treatments and novel mechanisms like baloxavir marboxil, expand treatment options. Quadrivalent and high-dose vaccines offer diverse demographic needs, while digital platforms aid vaccine monitoring and distribution. A robust government backing, ongoing research and development, and constantly evolving vaccine formulations contribute to long-term market expansion and resilience against influenza hazards.
Influenza Regional Market Analysis
North America holds a leading 44.5% share of the global influenza market in 2024, thanks to increased awareness, advanced healthcare systems, and robust government backing for vaccination initiatives. The region's growth is also driven by rapid vaccine development, digital platforms for tracking vaccinations, and strategic partnerships within the pharmaceutical industry. In contrast, the Asia-Pacific region is anticipated to be the fastest-growing market, projected to grow at a 6% CAGR from 2024 to 2030, fueled by increasing healthcare investments, rising flu cases, and expanded vaccination programs in countries like China, India, and Southeast Asia. Government policies, domestic vaccine manufacturing, and increased awareness are contributing to market growth. The region's large population and increased transmission rates drive demand, while technology transfer collaborations and innovative treatment options further enhance the market.
Influenza Market Analysis by Product
The influenza vaccines segment leads the market with an estimated 88.2% share in 2024 and is also the fastest-growing segment, anticipated to record a 4.7% CAGR from 2024 to 2030, driven by increasing immunization campaigns, governmental support, and endorsements from global health organizations such as WHO and CDC. The global vaccines volume market is estimated at 847.2 million doses in 2024, driven by the growth of immunization programs, increased flu awareness, improved access in developing regions, and government-led vaccination efforts. A rise in seasonal flu outbreaks, preparations for pandemics, and innovations in mRNA and recombinant vaccine sciences also enhance market demand. Furthermore, the growing elderly populations at higher risk contribute to market expansion. Conversely, the therapeutics segment grows slowly due to high vaccination rates, though advancements in antiviral drugs continue to address breakthrough infections.
Influenza Vaccines Market by Type
The quadrivalent segment dominated the influenza vaccine market in 2024, accounting for 79.3% of the share, and exhibited the fastest CAGR of 5.2% from 2024 to 2030, fueled by greater efficacy, broader protection against two strains each of influenza A and B, and a growing preference among healthcare providers. The growth is also supported by increasing product approvals, ambitious immunization goals, and growing adoption rates in developed and developing regions. Their presence in hospitals and clinics, cost-effective nature, and increasing public awareness have driven demand. Furthermore, the development of pipeline candidates and ongoing innovations contribute to their market growth. On the other hand, trivalent vaccines are growing slowly due to their restricted coverage as the industry progressively shifts toward quadrivalent formulations to adapt to the changing patterns of the influenza virus.
Influenza Therapeutics Market by Drug Type
In 2024, the oseltamivir phosphate segment led the market with a 47.4% share thanks to its strong effectiveness, broad activity against influenza A & B, and broad availability. As a neuraminidase inhibitor, it blocks viral replication, which reduces symptom severity and duration when taken early. The medication is primarily recommended for treatment and prevention, which enhances its market leadership. Continued research and development efforts focused on new formulations further drive this market growth. Conversely, baloxavir marboxil is the fastest-growing segment, projected to record a CAGR of 5% during the analysis period 2024-2030, attributed to its single-dose administration, enhanced patient compliance, and efficacy against drug-resistant influenza strains. Its capacity to inhibit viral replication early on makes it a compelling option compared to traditional multi-dose treatments.
Influenza Market Analysis by Age Group
In 2024, the adult segment is the largest in the influenza market by age group, with a 66.7% share, propelled by elevated vaccination rates among seniors and individuals with chronic illnesses. Government vaccination programs and large-scale procurement by PAHO, UNICEF, and GAVI have improved coverage, reducing influenza-related hospitalizations and fatalities. Prioritizing adult vaccination has become essential to safeguard high-risk groups. On the contrary, the pediatric segment is experiencing the fastest growth, with a projected 5% CAGR from 2024 to 2030, driven by boosted childhood immunization programs and the introduction of needle-free nasal spray vaccines. Increasing rates of influenza infections among children, population growth in emerging markets, and broadened vaccine age indications further fuel the expansion of the pediatric segment. Strategies by the WHO and CDC to ensure global vaccination for all children also play a significant role in this growth.
Influenza Market Analysis by Route of Administration
The injection segment is the largest market, holding an estimated share of 85.4% in the influenza market in 2024. Injectables are preferred in national immunization initiatives due to their robust immune response, consistent production standards, and extensive clinical efficacy and safety data. Their broad availability, comprehensive product range, and recent approvals contribute to the ongoing market expansion. Injectable vaccines generate stronger and longer-lasting antibody responses than nasal sprays, making them the preferred option for healthcare professionals and insurers. In contrast, the nasal spray segment is experiencing the fastest growth, with an anticipated CAGR of 6.9% until 2030, spurred by ease of administration, adaptability for personal use, and enhanced adherence, especially in children and those who fear needles. Continued research into intranasal vaccines, which have the potential to generate both systemic and mucosal immunity, further supports their increasing acceptance.
Influenza Market Analysis by Technology
The influenza market is primarily led by egg-based manufacturing, which commands a 62.5% market share in 2024, thanks to its established infrastructure and capacity for large-scale production. Even with hurdles such as extended production times and concerns regarding egg allergies, ongoing innovations are aimed at enhancing efficiency and output. On the other hand, recombinant DNA technology is experiencing the fastest growth, with a 7% CAGR over 2024-2030, as it removes the reliance on eggs, allowing for quicker vaccine development and responsiveness to new strains. Additionally, cell-based manufacturing is growing due to its ability to scale and lower the risk of antigenic drift, making it an appealing alternative to conventional methods.
Influenza Market Analysis by Distribution Channel
Hospital and retail pharmacies dominate the influenza market with a 51.8% share in 2024, acting as key access points for vaccines and treatments. Their leadership is supported by elevated hospitalization rates, increasing flu-related admissions, and the widespread availability of vaccines in smaller healthcare facilities. The growth of in-hospital pharmacies and the rising trend of over-the-counter drug use also contribute significantly to market expansion. In contrast, government suppliers represent the fastest-growing distribution channel, showing a 5.9% CAGR through 2030, driven by large-scale vaccine purchases for national immunization initiatives and pandemic readiness. Additionally, collaborations between public and private sectors, along with global health organizations, are enhancing the availability of affordable vaccines in underserved areas, further promoting the growth of this segment.
Influenza Market Report Scope
This global report on Influenza analyzes the market based on product, subtype, age group, route of administration, technology, and distribution channel for the period 2021-2030 with projections from 2024 to 2030 in terms of value in US$. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.
Key Metrics
Historical Period: 2021-2023
Base Year: 2024
Forecast Period: 2024-2030
Units: Value market in US$
Companies Mentioned: 20+
Influenza Market by Geographic Region
North America (The United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe)
Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
South America (Brazil, Argentina, and Rest of South America)
Rest of World
Influenza Market by Product
Vaccines
o Quadrivalent
o Trivalent
Therapeutics
o Oseltamivir Phosphate
o Zanamivir
o Peramivir
o Baloxavir Marboxil
o Others (Including Amantadine, Rimantadine, and Emerging Drugs)
Influenza Market by Age Group
Pediatrics
Adults
Influenza Market by Route of Administration
Injection
Oral
Nasal Spray
Influenza Market by Technology
Egg-based Manufacturing
Cell-based Manufacturing
Recombinant DNA Technology
Influenza Market by Distribution Channel
Hospital & Retail Pharmacies
Government Suppliers
Other Distribution Channels (Including Online Pharmacies, Private Clinics, Specialty Healthcare Centers, and others)
PART A: GLOBAL MARKET PERSPECTIVE
1. INTRODUCTION
- Product Outline
- Influenza Definition
- Influenza Products
o Vaccines
- Quadrivalent
- Trivalent
o Therapeutics
- Oseltamivir Phosphate
- Zanamivir
- Peramivir
- Baloxavir Marboxil
- Others (Including Amantadine, Rimantadine, and Emerging Drugs)
- Influenza Age Groups
o Pediatrics
o Adults
- Influenza Route of Administration
o Injection
o Oral
o Nasal Spray
- Influenza Technologies
o Egg-based Manufacturing
o Cell-based Manufacturing
o Recombinant DNA Technology
- Influenza Distribution Channels
o Hospital & Retail Pharmacies
o Government Suppliers
o Other Distribution Channels (Including Online Pharmacies, Private Clinics, Specialty Healthcare Centers, and others)
2. Key Market Trends
3. Key Global Players
- Abbott Laboratories, Inc.
- AstraZeneca plc
- BioCryst Pharmaceuticals, Inc.
- CSL Seqirus
- Daiichi Sankyo Company, Limited
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche AG
- GSK plc
- Hualan Biological Vaccine Inc
- Instituto Butantan
- Mitsubishi Tanabe Pharma Corporation
- NATCO Pharma Limited.
- Novavax, Inc.
- Pfizer Inc.
- Sanofi S.A.
- Shanghai Institute of Biological Products Co., Ltd.
- Shionogi & Co., Ltd.
- Sinovac Biotech Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
4. Key Business & Product Trends
5. Global Market Overview
- Global Influenza Market Overview by Product
o Influenza Product Market Overview by Global Region
- Vaccines
- Global Influenza Vaccines Volume Market Overview by Global Region
- Global Influenza Vaccines Market Overview by Type
- Influenza Vaccines Type Market Overview by Global Region
- Quadrivalent
- Trivalent
- Therapeutics
- Global Influenza Therapeutics Market Overview by Drug Type
- Influenza Therapeutics Drug Type Market Overview by Global Region
- Oseltamivir Phosphate
- Zanamivir
- Peramivir
- Baloxavir Marboxil
- Others
- Global Influenza Market Overview by Age Group
o Influenza Age Group Market Overview by Global Region
- Pediatrics
- Adults
- Global Influenza Market Overview by Route of Administration
o Influenza Route of Administration Market Overview by Global Region
- Injection
- Oral
- Nasal Spray
- Global Influenza Market Overview by Technology
o Influenza Technology Market Overview by Global Region
- Egg-based Manufacturing
- Cell-based Manufacturing
- Recombinant DNA Technology
- Global Influenza Market Overview by Distribution Channel
o Influenza Distribution Channel Market Overview by Global Region
- Hospital & Retail Pharmacies
- Government Suppliers
- Other Distribution Channels
PART B: REGIONAL MARKET PERSPECTIVE
- Global Influenza Market Overview by Geographic Region
REGIONAL MARKET OVERVIEW
6. North America
- North American Influenza Market Overview by Geographic Region
- North American Influenza Market Overview by Product
- North American Influenza Vaccines Market Overview by Type
- North American Influenza Therapeutics Market Overview by Drug Type
- North American Influenza Market Overview by Age Group
- North American Influenza Market Overview by Route of Administration
- North American Influenza Market Overview by Technology
- North American Influenza Market Overview by Distribution Channel
- Country-wise Analysis of North American Influenza Market
o The United States
- United States Influenza Market Overview by Product
- United States Influenza Vaccines Market Overview by Type
- United States Influenza Therapeutics Market Overview by Drug Type
- United States Influenza Market Overview by Age Group
- United States Influenza Market Overview by Route of Administration
- United States Influenza Market Overview by Technology
- United States Influenza Market Overview by Distribution Channel
o Canada
- Canadian Influenza Market Overview by Product
- Canadian Influenza Vaccines Market Overview by Type
- Canadian Influenza Therapeutics Market Overview by Drug Type
- Canadian Influenza Market Overview by Age Group
- Canadian Influenza Market Overview by Route of Administration
- Canadian Influenza Market Overview by Technology
- Canadian Influenza Market Overview by Distribution Channel
o Mexico
- Mexican Influenza Market Overview by Product
- Mexican Influenza Vaccines Market Overview by Type
- Mexican Influenza Therapeutics Market Overview by Drug Type
- Mexican Influenza Market Overview by Age Group
- Mexican Influenza Market Overview by Route of Administration
- Mexican Influenza Market Overview by Technology
- Mexican Influenza Market Overview by Distribution Channel
7. Europe
- European Influenza Market Overview by Geographic Region
- European Influenza Market Overview by Product
- European Influenza Vaccines Market Overview by Type
- European Influenza Therapeutics Market Overview by Drug Type
- European Influenza Market Overview by Age Group
- European Influenza Market Overview by Route of Administration
- European Influenza Market Overview by Technology
- European Influenza Market Overview by Distribution Channel
- Country-wise Analysis of European Influenza Market
o Germany
- German Influenza Market Overview by Product
- German Influenza Vaccines Market Overview by Type
- German Influenza Therapeutics Market Overview by Drug Type
- German Influenza Market Overview by Age Group
- German Influenza Market Overview by Route of Administration
- German Influenza Market Overview by Technology
- German Influenza Market Overview by Distribution Channel
o France
- French Influenza Market Overview by Product
- French Influenza Vaccines Market Overview by Type
- French Influenza Therapeutics Market Overview by Drug Type
- French Influenza Market Overview by Age Group
- French Influenza Market Overview by Route of Administration
- French Influenza Market Overview by Technology
- French Influenza Market Overview by Distribution Channel
o The United Kingdom
- United Kingdom Influenza Market Overview by Product
- United Kingdom Influenza Vaccines Market Overview by Type
- United Kingdom Influenza Therapeutics Market Overview by Drug Type
- United Kingdom Influenza Market Overview by Age Group
- United Kingdom Influenza Market Overview by Route of Administration
- United Kingdom Influenza Market Overview by Technology
- United Kingdom Influenza Market Overview by Distribution Channel
o Italy
- Italian Influenza Market Overview by Product
- Italian Influenza Vaccines Market Overview by Type
- Italian Influenza Therapeutics Market Overview by Drug Type
- Italian Influenza Market Overview by Age Group
- Italian Influenza Market Overview by Route of Administration
- Italian Influenza Market Overview by Technology
- Italian Influenza Market Overview by Distribution Channel
o Spain
- Spanish Influenza Market Overview by Product
- Spanish Influenza Vaccines Market Overview by Type
- Spanish Influenza Therapeutics Market Overview by Drug Type
- Spanish Influenza Market Overview by Age Group
- Spanish Influenza Market Overview by Route of Administration
- Spanish Influenza Market Overview by Technology
- Spanish Influenza Market Overview by Distribution Channel
o Rest of Europe
- Rest of Europe Influenza Market Overview by Product
- Rest of Europe Influenza Vaccines Market Overview by Type
- Rest of Europe Influenza Therapeutics Market Overview by Drug Type
- Rest of Europe Influenza Market Overview by Age Group
- Rest of Europe Influenza Market Overview by Route of Administration
- Rest of Europe Influenza Market Overview by Technology
- Rest of Europe Influenza Market Overview by Distribution Channel
8. Asia-Pacific
- Asia-Pacific Influenza Market Overview by Geographic Region
- Asia-Pacific Influenza Market Overview by Product
- Asia-Pacific Influenza Vaccines Market Overview by Type
- Asia-Pacific Influenza Therapeutics Market Overview by Drug Type
- Asia-Pacific Influenza Market Overview by Age Group
- Asia-Pacific Influenza Market Overview by Route of Administration
- Asia-Pacific Influenza Market Overview by Technology
- Asia-Pacific Influenza Market Overview by Distribution Channel
- Country-wise Analysis of Asia-Pacific Influenza Market
o Japan
- Japanese Influenza Market Overview by Product
- Japanese Influenza Vaccines Market Overview by Type
- Japanese Influenza Therapeutics Market Overview by Drug Type
- Japanese Influenza Market Overview by Age Group
- Japanese Influenza Market Overview by Route of Administration
- Japanese Influenza Market Overview by Technology
- Japanese Influenza Market Overview by Distribution Channel
o China
- Chinese Influenza Market Overview by Product
- Chinese Influenza Vaccines Market Overview by Type
- Chinese Influenza Therapeutics Market Overview by Drug Type
- Chinese Influenza Market Overview by Age Group
- Chinese Influenza Market Overview by Route of Administration
- Chinese Influenza Market Overview by Technology
- Chinese Influenza Market Overview by Distribution Channel
o India
- Indian Influenza Market Overview by Product
- Indian Influenza Vaccines Market Overview by Type
- Indian Influenza Therapeutics Market Overview by Drug Type
- Indian Influenza Market Overview by Age Group
- Indian Influenza Market Overview by Route of Administration
- Indian Influenza Market Overview by Technology
- Indian Influenza Market Overview by Distribution Channel
o South Korea
- South Korean Influenza Market Overview by Product
- South Korean Influenza Vaccines Market Overview by Type
- South Korean Influenza Therapeutics Market Overview by Drug Type
- South Korean Influenza Market Overview by Age Group
- South Korean Influenza Market Overview by Route of Administration
- South Korean Influenza Market Overview by Technology
- South Korean Influenza Market Overview by Distribution Channel
o Rest of Asia-Pacific
- Rest of Asia-Pacific Influenza Market Overview by Product
- Rest of Asia-Pacific Influenza Vaccines Market Overview by Type
- Rest of Asia-Pacific Influenza Therapeutics Market Overview by Drug Type
- Rest of Asia-Pacific Influenza Market Overview by Age Group
- Rest of Asia-Pacific Influenza Market Overview by Route of Administration
- Rest of Asia-Pacific Influenza Market Overview by Technology
- Rest of Asia-Pacific Influenza Market Overview by Distribution Channel
9. South America
- South American Influenza Market Overview by Geographic Region
- South American Influenza Market Overview by Product
- South American Influenza Vaccines Market Overview by Type
- South American Influenza Therapeutics Market Overview by Drug Type
- South American Influenza Market Overview by Age Group
- South American Influenza Market Overview by Route of Administration
- South American Influenza Market Overview by Technology
- South American Influenza Market Overview by Distribution Channel
- Country-wise Analysis of South American Influenza Market
o Brazil
- Brazilian Influenza Market Overview by Product
- Brazilian Influenza Vaccines Market Overview by Type
- Brazilian Influenza Therapeutics Market Overview by Drug Type
- Brazilian Influenza Market Overview by Age Group
- Brazilian Influenza Market Overview by Route of Administration
- Brazilian Influenza Market Overview by Technology
- Brazilian Influenza Market Overview by Distribution Channel
o Argentina
- Argentine Influenza Market Overview by Product
- Argentine Influenza Vaccines Market Overview by Type
- Argentine Influenza Therapeutics Market Overview by Drug Type
- Argentine Influenza Market Overview by Age Group
- Argentine Influenza Market Overview by Route of Administration
- Argentine Influenza Market Overview by Technology
- Argentine Influenza Market Overview by Distribution Channel
o Rest of South America
- Rest of South American Influenza Market Overview by Product
- Rest of South American Influenza Vaccines Market Overview by Type
- Rest of South American Influenza Therapeutics Market Overview by Drug Type
- Rest of South American Influenza Market Overview by Age Group
- Rest of South American Influenza Market Overview by Route of Administration
- Rest of South American Influenza Market Overview by Technology
- Rest of South American Influenza Market Overview by Distribution Channel
10. Rest of World
- Rest of World Influenza Market Overview by Product
- Rest of World Influenza Vaccines Market Overview by Type
- Rest of World Influenza Therapeutics Market Overview by Drug Type
- Rest of World Influenza Market Overview by Age Group
- Rest of World Influenza Market Overview by Route of Administration
- Rest of World Influenza Market Overview by Technology
- Rest of World Influenza Market Overview by Distribution Channel
PART C: GUIDE TO THE INDUSTRY
PART D: ANNEXURE
1. RESEARCH METHODOLOGY
2. FEEDBACK
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security